Cetuximab added to radiotherapy improves patients' survival in head and neck cancer

摘要

Patients with locally advanced squamous cell carcinoma of the head and neck have improved control and overall survival is increased it cetuximab .(Erbitux,developed by ImClone)is added to their high-dose radiotherapy regimen.So said James Bonner,professor ot radiation oncology.University of Alabama,when he presented results of a phase III trial.